Novavax Offers U.S. a Fourth Strong Covid-19 Vaccine

The company ’s large U.S. trial found an efficacy rate of about 90 percent. But at this point, the nation is awash in other shots.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Clinical Trials Vaccination and Immunization Coronavirus (2019-nCoV) Public-Private Sector Cooperation Novavax Inc Factories and Manufacturing your-feed-healthcare Source Type: news